HDEP-28

HDEP-28 or ethylnaphthidate is a piperidine based stimulant drug, closely related to ethylphenidate, but with the benzene ring replaced by naphthalene. It is even more closely related to HDMP-28, which acts as a potent serotonin–norepinephrine–dopamine reuptake inhibitor with several times the potency of methylphenidate and a short duration of action.^[1] It has been sold as a designer drug since around 2015.^[2]

HDEP-28

Legal status
Legal status	CA: Schedule III DE: NpSG (Industrial and scientific use only) UK: Class B
Identifiers
IUPAC name Ethyl (naphthalen-2-yl)(piperidin-2-yl)acetate
CAS Number	2170529-69-6
PubChem CID	91844468
ChemSpider	52085106
UNII	A8326SH248
CompTox Dashboard (EPA)	DTXSID601336139
Chemical and physical data
Formula	C19H23NO2
Molar mass	297.398 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)C(C1CCCCN1)c2ccc3ccccc3c2
InChI InChI=1S/C19H23NO2/c1-2-22-19(21)18(17-9-5-6-12-20-17)16-11-10-14-7-3-4-8-15(14)13-16/h3-4,7-8,10-11,13,17-18,20H,2,5-6,9,12H2,1H3 Key:OTQVTBPHZRARTL-UHFFFAOYSA-N

Legality

HDEP-28 was banned in the UK as a Temporary Class Drug from June 2015 following its unapproved sale as a designer drug, alongside 4-Methylmethylphenidate.^[3][4][5]

See also

• 2β-Propanoyl-3β-(2-naphthyl)-tropane (WF-23)
• 3,4-Dichloromethylphenidate
• 4-Methylmethylphenidate
• 4-Fluoromethylphenidate
• Isopropylphenidate
• Naphthylisopropylamine
• Naphyrone
• Propylphenidate

References

1. Lile JA, Wang Z, Woolverton WL, France JE, Gregg TC, Davies HM, et al. (October 2003). "The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics". The Journal of Pharmacology and Experimental Therapeutics. 307 (1): 356–66. doi:10.1124/jpet.103.049825. PMID 12954808. S2CID 5654856.
2. Luethi D, Kaeser PJ, Brandt SD, Krähenbühl S, Hoener MC, Liechti ME (May 2018). "Pharmacological profile of methylphenidate-based designer drugs" (PDF). Neuropharmacology. 134 (Pt A): 133–140. doi:10.1016/j.neuropharm.2017.08.020. PMID 28823611.
3. "Methylphenidate-based NPS: A review of the evidence of use and harm" (PDF). Advisory Council on the Misuse of Drugs. 31 March 2015.
4. "Letter to Mike Penning on methylphenidate-based novel psychoactive substances". Advisory Council on the Misuse of Drugs. 25 June 2015. Retrieved 25 June 2015.
5. "Ministerial response to the Advisory Council on the Misuse of Drugs about 2 new methylphenidate-based substances". Home Office. 25 June 2015. Retrieved 25 June 2015.